Nitanai T[au] - Search Results

Year	Number of Results
1980	2
1981	2
1983	1
1984	1
1990	1
1997	1
2005	1
2007	1
2008	1
2015	1
2016	1
2023	0

1

Dosage form design for improvement of bioavailability of levodopa VI: formulation of effervescent enteric-coated tablets.

Nishimura K, Sasahara K, Arai M, Nitanai T, Ikegami Y, Morioka T, Nakajima E. Nishimura K, et al. Among authors: nitanai t. J Pharm Sci. 1984 Jul;73(7):942-6. doi: 10.1002/jps.2600730720. J Pharm Sci. 1984. PMID: 6088756

2

Optimization of Look-Locker Turbo-Field Echo-Planar Imaging and Evaluation of Its Accuracy in Head and Neck 3D T1 Mapping.

Maehara M, Monma M, Nitanai T, Matsumoto T, Fukuma Y. Maehara M, et al. Among authors: nitanai t. Magn Reson Med Sci. 2016 Jul 11;15(3):288-98. doi: 10.2463/mrms.mp.2015-0057. Epub 2015 Dec 28. Magn Reson Med Sci. 2016. PMID: 26726016 Free PMC article.

3

Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients.

Sasahara K, Nitanai T, Habara T, Morioka T, Nakajima E. Sasahara K, et al. Among authors: nitanai t. J Pharm Sci. 1980 Dec;69(12):1374-8. doi: 10.1002/jps.2600691205. J Pharm Sci. 1980. PMID: 7463319

4

Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients.

Sasahara K, Nitanai T, Habara T, Morioka T, Nakajima E. Sasahara K, et al. Among authors: nitanai t. J Pharm Sci. 1980 May;69(3):261-5. doi: 10.1002/jps.2600690304. J Pharm Sci. 1980. PMID: 7381698

5

Isolation and identification of diglucuronides of some endogenous steroids in dogs.

Murai T, Yamamura N, Nitanai T, Samata N, Takei M, Iwabuchi H, Tanaka K, Mikamoto K, Ikeda T. Murai T, et al. Among authors: nitanai t. Drug Metab Dispos. 2008 Feb;36(2):368-74. doi: 10.1124/dmd.107.019059. Epub 2007 Nov 15. Drug Metab Dispos. 2008. PMID: 18006648

6

Dosage form design for improvement of bioavailability of levodopa V: Absorption and metabolism of levodopa in intestinal segments of dogs.

Sasahara K, Nitanai T, Habara T, Morioka T, Nakajima E. Sasahara K, et al. Among authors: nitanai t. J Pharm Sci. 1981 Oct;70(10):1157-60. doi: 10.1002/jps.2600701018. J Pharm Sci. 1981. PMID: 7299652

7

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs.

Sasahara K, Nitanai T, Habara T, Kojima T, Kawahara Y, Morioka T, Nakajima E. Sasahara K, et al. Among authors: nitanai t. J Pharm Sci. 1981 Jul;70(7):730-3. doi: 10.1002/jps.2600700705. J Pharm Sci. 1981. PMID: 7264915

8

Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes.

Takasaki W, Yamamura M, Nozaki A, Nitanai T, Sasahara K, Itoh K, Tanaka Y. Takasaki W, et al. Among authors: nitanai t. Chirality. 2005 Mar;17(3):135-41. doi: 10.1002/chir.20124. Chirality. 2005. PMID: 15704197

9

Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up.

Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, Kobayashi T. Mitsuhashi Y, et al. Among authors: nitanai t. Cancer Chemother Pharmacol. 1990;27(1):20-6. doi: 10.1007/BF00689271. Cancer Chemother Pharmacol. 1990. PMID: 2245489

10

The pharmacokinetic profile of RS-8359.

Püchler K, Sasahara K, Plenker A, Nitanai T, Witte PU. Püchler K, et al. Among authors: nitanai t. Int Clin Psychopharmacol. 1997 Sep;12 Suppl 5:S11-6. doi: 10.1097/00004850-199709005-00003. Int Clin Psychopharmacol. 1997. PMID: 9466164 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results